Technical advance in targeted NGS analysis enables identification of lung cancer risk-associated low frequency TP53, PIK3CA, and BRAF mutations in airway epithelial cells

Table 3 Statistical analysis of target specific inter-cohort differences in mutation prevalence

Target	CA-SMK vs. NC-TOT	CA-SMK vs. NC-SMK	CA-SMK vs. NC-NON	NC-SMK vs. NC-NON
BRAF_15	0.12	0.4	0.54	1
EGFR_18	N/A	N/A	N/A	N/A
EGFR_19	N/A	N/A	N/A	N/A
EGFR_20	0.72	0.78	0.96	0.74
EGFR_21	0.39	0.76	0.83	1
ERBB2	0.35	0.73	0.8	1
KRAS_2	N/A	N/A	N/A	N/A
PIK3CA_10	0.062	0.27	0.41	1
TP53_5	0.022	0.27	0.1	0.77
TP53_6	0.0083	0.037	0.333	0.849
TP53_7	0.028	0.25	0.16	0.9
TP53_Total	0.0019	0.047	0.043	0.92

p-value for differences in mutation prevalence in each target across cohorts was measured with Kruskal-Wallis test and p-values presented were adjusted for multiple comparisons using Nemenyi test. Mutations were defined as those with VAF (variant allele reads/total allele reads) > 5 × 10^− 4 and significantly above IS background VAF based on contingency table analysis

ISSN: 1471-2407